Treatment of Pancreatic Cancer Sacramento CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Suzanne Eileen Generao, MD
(916) 733-5005
2801 K St Ste 205
Sacramento, CA
Specialties
Urology
Gender
Female
Education
Medical School: Georgetown Univ Sch Of Med, Washington Dc 20007
Graduation Year: 1999

Data Provided by:
Frederick Runkel Burrell, MD
(916) 733-3310
3160 Folsom Blvd
Sacramento, CA
Specialties
Urology
Gender
Male
Education
Medical School: Baylor Coll Of Med, Houston Tx 77030
Graduation Year: 1958
Hospital
Hospital: Sutter Gen Hosp, Sacramento, Ca; Mercy Gen Hosp, Sacramento, Ca
Group Practice: Med Clinic

Data Provided by:
Herbert Francis Cronin, MD
(916) 488-3754
5025 J St Ste 312
Sacramento, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Pittsburgh Sch Of Med, Pittsburgh Pa 15261
Graduation Year: 1957

Data Provided by:
Brad Robert Nanigian, MD
Sacramento, CA
Specialties
Urology
Gender
Male
Education
Medical School: Temple Univ Sch Of Med, Philadelphia Pa 19140
Graduation Year: 2000

Data Provided by:
Roger Kennedy Low, MD
(916) 734-2893
4860 Y St Ste 3500
Sacramento, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Vt Coll Of Med, Burlington Vt 05405
Graduation Year: 1988

Data Provided by:
Louis John Giorgi
(916) 733-5005
2801 K Street
Sacramento, CA
Specialty
Urology

Data Provided by:
Iraj Nabi, MD
(209) 847-2554
3160 Folsom Blvd
Sacramento, CA
Specialties
Urology
Gender
Male
Education
Medical School: Shiraz Univ Of Med Sci, Shiraz, Iran
Graduation Year: 1971

Data Provided by:
Kiumars Hekmat, MD
(916) 733-6233
3939 J St Ste 250
Sacramento, CA
Specialties
Urology
Gender
Male
Education
Medical School: Shiraz Univ Of Med Sci, Shiraz, Iran
Graduation Year: 1971

Data Provided by:
Dr.Iraj Nabi
(916) 739-1400
3939 J Street
Sacramento, CA
Gender
M
Education
Medical School: Shiraz Univ Of Med Sci, Shiraz
Year of Graduation: 1971
Speciality
Urologist
General Information
Accepting New Patients: Yes
RateMD Rating
3.6, out of 5 based on 5, reviews.

Data Provided by:
Udayshanka R Poonamallee, MD
(916) 733-6233
3939 J St Ste 250
Sacramento, CA
Specialties
Urology
Gender
Male
Education
Medical School: New York Univ Sch Of Med, New York Ny 10016
Graduation Year: 1985

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com